Comparing the current results to its competitors, Legend Biotech reported Revenue increase in the 4 quarter 2025 by 451.62 % year on year. The sales growth was above Legend Biotech's competitors' average revenue growth of 9.23 %, achieved in the same quarter.
Legend Biotech Corporation, despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 42.55 %
Legend Biotech's Comment on Competition and Industry Peers
The company faces competition from novel therapies developed by biopharmaceutical companies, academic research institutions, governmental agencies, and public and private research institutions, as well as from standard of care treatments. Notable competitors include Novartis, which offers Kymriah for the treatment of children and young adults with acute lymphoblastic leukemia (ALL) and adults with relapsed or refractory diffuse large B cell lymphoma (DLBCL), and Kite, which markets Yescarta for adult patients with relapsed or refractory large B-cell lymphoma and follicular lymphoma, and Tecartus for related conditions. The company cites its scalable manufacturing process, proprietary technologies, and experienced team as factors contributing to its competitive position.
Due to outstanding performance in Overall company, revenue grew by 451.62 % Legend Biotech Corporation improved its market share, to approximately 0.34 %.
November 13, 2025
In the rapidly evolving field of cell therapy, Legend Biotech Corporation stands out as a leader in innovation and sustainability. This article reviews the recent endeavors undertaken by Legend Biotech, including the official opening of its state-of-the-art cell therapy research and development facility in Philadelphia and the publication of its inaugural Environmental, Social, and Governance (ESG) report. These milestones not only enhance the company’s operational capacity but also reinforce its commitment to responsible corporate practices in line with its strategic goals.Cell therapy represents a transformative approach in modern medicine, particularly in the treatment of malignancies like multiple myel...
October 3, 2024
The landscape of pharmaceutical sciences is rapidly evolving, particularly in the field of cell therapy. Advances in technology and significant investment in research and development are crucial for maintaining leadership in this innovative field. In this context, Legend Biotech has announced the establishment of a new, state-of-the-art cell therapy research and development facility in Philadelphia, signaling a bold commitment to further enhancing its already robust portfolio and global capabilities. A Strategic Expansion Spanning an impressive 31,000 square feet, the new facility is set to become a hub for cutting-edge research in cell therapy. Legend Biotech aims to not only enhance its existing cell thera...
July 2, 2024
Legend Biotech Announces Promising Advancement in Multiple Myeloma Treatment: Landmark Phase 3 CARTITUDE-4 Trial Showcases Positive Overall Survival Results for CARVYKTILegend Biotech, a global biotechnology leader, has announced encouraging results from its landmark Phase 3 CARTITUDE-4 clinical trial, highlighting a significant milestone in the treatment of multiple myeloma. The trial, which evaluates the efficacy of the company s CARVYKTI (cilta-cel), revealed statistically significant and clinically meaningful improvements in overall survival rates. This breakthrough marks a substantial advancement in the therapeutic landscape for patients battling this challenging form of blood cancer. CARVYKTI: A Hopefu...
June 4, 2024
:Legend Biotech Corporation, a renowned global leader in cell therapy, has unveiled groundbreaking results from the Phase 2 CARTITUDE-2 Cohort D study, showcasing the potential of CARVYKTI (ciltacabtagene autoleucel; cilta-cel) in the treatment of multiple myeloma patients. These findings indicate that patients with inadequate response to front-line autologous stem cell transplant (ASCT) experienced profound and long-lasting improvements after a single infusion of CARVYKTI. Furthermore, Legend Biotech will present additional data at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and the 2024 European Hematology Associations (EHA) Hybrid Congress, highlighting the efficacy and leadership...
May 29, 2024
CSIMarket.com Legend Biotech Corporation (NASDAQ: LEGN), a renowned global leader in cell therapy, is making significant strides in the development of CAR-T cell therapy for patients with multiple myeloma. The company has recently participated in the Jefferies Global Healthcare Conference and announced the presentation of new data from the CARTITUDE clinical development program at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and the 2024 European Hematology Associations (EHA) Hybrid Congress. Additionally, Legend Biotech has received approval from the European Commission for the second-line treatment of relapsed and refractory multiple myeloma patients with CARVYKTI (ciltacabtagene a...
May 23, 2024
SOMERSET, N.J. Legend Biotech Corporation (NASDAQ: LEGN), a global leader in cell therapy, is poised to make significant strides in the treatment of multiple myeloma through groundbreaking data and strategic collaborations. The company recently announced several pivotal advancements, including new and updated data from their CARTITUDE clinical development program featuring CARVYKTI (ciltacabtagene autoleucel; cilta-cel) and a significant new licensing agreement with Novartis. CARTITUDE Clinical Development Program at ASCO and EHA 2024Legend Biotech will present new and updated data from the CARTITUDE program at two of the most influential global medical conferences in 2024: the American Society of Clinica...
April 23, 2024
Europe Greenlights Ciltacabtagene Autoleucel for Treatment of Relapsed and Refractory Multiple Myeloma: A Major Breakthrough in Oncotherapy In a significant move in the field of oncotherapy, the European Commission (EC) has approved CARVYKTI (ciltacabtagene autoleucel, cilta-cel), developed by Legend Biotech Corporation, a globally recognized leader in cell therapy. Cilta-cel is now authorized for the treatment of adult patients diagnosed with relapsed and refractory multiple myeloma who have earlier received at least one prior line of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD), and have shown disease progression.Multiple myeloma is a type of blood cancer that affects...
March 15, 2024
SOMERSET, N.J. - In a significant development for patients suffering from relapsed or refractory multiple myeloma, CARVYKTI (ciltacabtagene autoleucel) has received a positive recommendation from the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC). This recommendation highlights CARVYKTI s efficacy and safety profile, paving the way for earlier treatment options for these patients.Legend Biotech Corporation (NASDAQ: LEGN), a leading global cell therapy company, made the announcement today. CARVYKTI, also known as cilta-cel, is being considered for adult patients who have relapsed or refractory multiple myeloma and have previously received at least one line of therapy, includ...
January 3, 2024
Legend Biotech (NASDAQ: LEGN), a trailblazer in the world of biotechnology, is devoted to developing, producing, and marketing pioneering therapies created to battle life-threatening diseases and conditions.The closed license agreement with Novartis will cover treatments spanning a range of specific therapies, including those associated with Legend Biotech s revolutionary autolus treatment. This medical breakthrough promotes personalized medicine by allowing a patient s cells to be genetically reprogrammed to fight against cancer. The Delta-like ligand protein 3 (DLL3) serves a pivotal role in the operation of CAR-T cell therapies. When the DLL3 gene mutates, it can lead to significant medical complications,...
Publicly Traded Peers of Legend Biotech Corporation
Disc Medicine Inc Share Performance
+8.06%
This Quarter
Disc Medicine Inc
Profile
Disc Medicine Inc is a biotechnology company that focuses on developing therapeutic treatments for hematologic diseases. Their business model revolves around leveraging their expertise in hepcidin biology to discover and develop small molecules that regulate iron metabolism. By targeting and modulating specific pathways, they aim to address unmet medical needs in conditions like iron overload disorders and anemia.
Immunome Inc is a biotechnology company that focuses on developing novel immunotherapies. Their business model revolves around leveraging their proprietary discovery engine to identify therapeutic antibodies for infectious diseases and cancer. By collaborating with partners and through their own clinical development efforts, they aim to bring these promising treatments to the market.
Oculis Holding Ag is a pharmaceutical company that specializes in developing and commercializing innovative ophthalmic treatments. Their business model revolves around conducting in-depth research and development to formulate eye medications that target various ocular diseases. They then seek regulatory approvals and form strategic partnerships to manufacture and distribute their products globally, aiming to improve eye health and provide effective treatment options for patients.
Third Harmonic Bio Inc's business model centers around developing and commercializing innovative therapeutic solutions through the utilization of bioinformatics and genomics.
Theravance Biopharma Inc's business model focuses on developing and commercializing innovative therapeutics to address unmet medical needs in various therapeutic areas.
Sources:
Legend Biotech Corporation’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Legend Biotech Corporation versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
